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To the editor:
We express our special thanks for these nice comments 
on our published paper in your journal [1]. Our study was 
done before the release of the mentioned new guidelines in 
2015 [2]. Moreover, there are studies that have also studied 
different outcomes (effect) of different durations of these 
medications on benign prostatic hyperplasia [3-5]. We were 
not able to study the maximal effect for more than 3 
months. Because of the lack of previous studies with our 
design, we preferred to run a study with a shorter duration. 
In addition, our study was a cohort based on the present 
data and not a clinical trial with an arbitrary duration of 
study.
Our treatment regimen contained both medications and 
we did not have a cohort of persons receiving only one of 
these medications. Perhaps in a factorial clinical trial with 
different groups consisting of only one of these medications, 
their combination and placebo could be useful for evaluation 
of the effect of each regimen. Surely, our results cannot be 
assumed to refer to only one of these medications but to 
their combination.
In response to the comment, “In addition, the clinical 
effects of  5ARIs are seen after a minimum treatment 
duration of at least 6 to 12 months,” we should note that 
in our study, the effects of  combination therapy had 
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been observed with a shorter duration. It may be that 
combination therapy is more effective with a shorter 
duration and that the effect of combination therapy with 
both finasteride and prazosin is different from their single 
treatment effect.
Finally, our study was a clinical study and not a basic 
evaluation of the hormones. Accordingly, we prefer to not 
discuss these issues, even though the authors’ opinions 
about hormonal pathways and changes seem logical. We 
think that these issues need a separate study evaluating the 
effect of all single or combination therapies on biochemical, 
hormonal, and enzymatic changes.
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